Mammography
Methodology & AI Transparency ⓘ
Mammography Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is a mammogram? A mammogram is an x-ray picture of the breast.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C43.6 for Mammography clinical workups.
- 3 Typical cash cost range: Workup highlights for Mammography (C43.6): targeted/immunotherapy [Mammography C43.6].
- 4 Top reported side effects / signs: Objective lab/clinical target for Mammography: Pathology / Molecular in Mammography (C43.6: Genomic Staging) (Guideline-concordant surveillance (C43.6)) and Complete Blood Count in Mammography (C43.6: (ANC, Hemoglobin, Platelets)).
Ask our AI Specialists anything about Mammography
What Is Mammography?
What is a mammogram? A mammogram is an x-ray picture of the breast. Health care providers use mammograms to look for early signs of breast cancer that can't be felt during a breast exam. There are two types of mammograms: screening mammograms and diagnostic mammograms. What is a screening mammogram? A screening mammogram is a mammogram usually done for women who have no signs or symptoms of breast cancer. Regular screening mammograms can help reduce the number of deaths from breast cancer among women ages 40 to 74. This is because they can find breast cancer early and treatment can start earlier, maybe before it has spread. But screening mammograms can also have risks.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in cancer & oncology, Mammography (C43.6) involves immune-checkpoint evasion [Mammography C43.6]. Cross-referenced with NIH MeSH (Mammography), progression correlates with shifts in Pathology / Molecular in Mammography (C43.6: Genomic Staging) (Guideline-concordant surveillance (C43.6)).
Common Symptoms & Clinical Signs
- • Presentation of Mammography (C43.6): unintended weight loss [Mammography C43.6]
- • Secondary Mammography clinical sign: unexplained bleeding, chronic in Mammography (C43.6: hoarseness/cough, or progressive)
- • Symptom flares in Mammography correlating with Pathology / Molecular in Mammography (C43.6: Genomic Staging) deviation outside Guideline-concordant surveillance (C43.6)
- • Functional cancer & oncology impact requiring targeted/immunotherapy [Mammography C43.6] evaluation (C43.6)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Mammography Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C43.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Mammography (C43.6: Genomic Staging) | Guideline-concordant surveillance (C43.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Mammography (C43.6: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C43.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Mammography (C43.6: Organ Function Panel) | Preserved renal/hepatic clearance (C43.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mammography
Treatment selection for Mammography depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mammography)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Eltrombopag during induction chemotherapy in older patients with newly diagnosed This study failed to demonstrate a survival advantage after eltrombopag addition, at variance with previous reports, but shows that initiating eltrombopag after chemotherapy washout is feasible and safe, and resulted in a... Cancer • 2026-11-01 • Randomized Controlled Trial | N = 110 | 88/100 | PMID 42963911 ↗ |
| Can This Approach Help? Inside the Latest Research on Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony Efbemalenograstim alfa is effective and safe for significantly decreasing the duration of severe neutropenia and the incidence of febrile neutropenia in breast cancer patients who are receiving TA chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • 2023-12-16 • Phase III Randomized Trial | N = 122 | 88/100 | PMID 38103088 ↗ |
| New Insights on Phase III randomized trial comparing palliative systemic therapy to best: What a 281-Participant Study Found BSC alone is no longer appropriate. International journal of cancer • 2024-12-15 • Phase III Randomized Trial | N = 281 | 87/100 | PMID 39093841 ↗ |
| What the Latest Evidence Really Says About Breast cancer risk for women with diabetes and the impact of Women with T2DM were more likely to be diagnosed with BC and this association was strengthened by adjusting for BMI and menopausal status. Cancer medicine • 2023-05-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 36533539 ↗ |
| Can This Approach Help? Inside the Latest Research on Quality of life and patient reported outcomes in the UK Mammo-50 randomised trial Women were concerned with co-morbidities or family problems and side-effects of treatment rather than worries about having less frequent mammograms. Health and quality of life outcomes • 2025-07-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40598487 ↗ |
Mammography Patient Community & “People Like Me” Threads
Filter Mammography community threads and patient logs by age, biological sex, dosage, and treatment duration.